Caris Life Sciences, a United States-based molecular science company, announced on Tuesday that it has named Matthew Oberley, MD, PhD, as its new executive medical director.
Dr Oberley joined the company in August 2019 as senior medical director and has functioned as a leading face for Caris' clinical and scientific expertise in the marketplace and research community. Prior to joining Caris, Dr Oberley held roles at the University of Southern California and, most recently, Children's Hospital Los Angeles.
His responsibilities have included managing the company's Medical Science Liaison team and helping connect key oncology research leaders across the country with the large datasets Caris has generated through the Company's molecular profiling technology. In his expanded role, Dr Oberley will manage the company's quality and fidelity of the medical operations facilities to ensure patient safety. Dr Oberley will lead Caris' pathology and genetics teams.
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART